Androgen replacement therapy, often referred to as testosterone replacement therapy is a form of hormone therapy in which androgens, often testosterone, are supplemented or replaced. It typically involves the administration of testosterone through injection, skin creams, patches, gels, pills, or subcutaneous pellets. Androgen replacement therapy is often prescribed to counter the effects of male hypogonadism. Androgen deficiencies in women have also, as of 2001, been recognized as a medical disorder that can be treated with androgen replacement therapy. As with men, symptoms associated with androgen deficiency are, most prevalent with age, and androgen replacement therapy has been shown to help with symptoms of menopause.
Androgen replacement is used in postmenopausal women, the indication is to increase sexual desire and to prevent or treat osteoporosis. Other symptoms of androgen deficiency are similar in both sexes, such as muscle loss and physical fatigue. For two decades transdermal testosterone preparation has been available and has an attractive pharmacokinetic profile. Scrotal testosterone patches generate supraphysiological plasma DHT levels, which is not the case with nonscrotal testosterone patches. Transdermal testosterone gel produces less skin irritation than the patches and offers greater flexibility in dosage. Clinicians need to prescribe androgen replacement therapy by using a risk-benefit assessment of individual patient’s clinical needs and risk of adverse reaction. Clinical use of androgen replacement therapy for the treatment of senile hypogonadism is growing rapidly. Such widespread application of this treatment modality warrants a critical review of both its purported benefits and its potential risks.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/androgen-replacement-therapy-market/
Global Androgen Replacement Therapy Market – Competitive Landscape
On November 14, 2022, MBX Bioscience secured USD 115 million to advance precision endocrine peptides. On October 27, 2022, Tolmar announced the acquisition of JATENZO® for the treatment of hypogonadism to expand its market-leading urology portfolio. On August 24, 2022, Plume, a startup focused on virtual care for transgender patients raised USD 24 million in series B funding. On April 6, 2022, Evernow, a telehealth company dedicated to using science to transform care for women in perimenopause and menopause announced USD 28.5 million in series A funding.
Some of the Key Players in the Global Androgen Replacement Therapy Market Include –
- AbbVie Inc.
- Endo Pharmaceutical Inc.
- Pfizer
- Eli Lilly and Company
- Allergan Plc.
- Bayer AG
- Mylan N.V.
- Ferring Holding SA
Global Androgen Replacement Therapy Market – Growth Drivers
As the global population ages, there’s a higher incidence of age-related hormonal imbalances particularly in men, driving the demand for androgen replacement therapy. Growing awareness among both healthcare professionals and the general population regarding hormonal disorders, such as hypogonadism, contributes to an increased diagnosis and subsequent treatment with androgen replacement therapy. The rising prevalence of hypogonadism, a condition characterized by inadequate testosterone production, is a significant factor fueling the demand for androgen replacement therapy. According to the National Center for Biotechnology Information (NCBI), the crude prevalence rate of hypogonadism was 38.7%. for every 10-year increase in age, a patient’s risk of hypogonadism increased by 17%. Ongoing advancements in medical technology including the development of innovative and more effective therapeutic formulations, enhance the efficiency and acceptance of androgen replacement therapies. Modern sedentary lifestyles and environmental factors contribute to hormonal imbalances, fostering the need for androgen replacement therapy to address related health issues. The introduction of diverse androgen replacement therapy options, such as patches, gels, injections, and implants, provides patients with choices, contributing to global androgen replacement therapy market expansion.
Global Androgen Replacement Therapy Market – Restraints
Concerns regarding potential side effects and the long-term safety of androgen replacement therapy, including cardiovascular risk and prostate-related issues, can limit widespread acceptance and usage. Regulatory scrutiny and stringent approval processes for new androgen replacement therapies may delay global androgen replacement market entry and limit the number of available treatment options. The availability of alternative treatments and therapies such as lifestyle modification and alternative medicine, may divert patients away from androgen replacement therapy. The cost associated with androgen replacement therapy, including medication and monitoring, can be significant barriers, particularly in regions with limited healthcare resources and coverages. According to the National Center for Biotechnology Information (NCBI), the cost of testosterone replacement therapy per month is USD 201.33. In some regions there may be a lack of awareness about hormonal disorders and available treatment options, hindering the adoption of androgen replacement therapy. Androgen replacement therapies, particularly anabolic steroids, have the potential for misuse or abuse, leading to regulatory challenges and negative perceptions.
Global Androgen Replacement Therapy Market – Opportunities
Opportunities exist to raise awareness about hormonal disorders and the benefits of androgen replacement therapy through educational campaigns, potentially expanding the market by reaching more individuals who may benefit from these treatments. Penetration into untapped markets and regions with a lower awareness of androgen replacement therapy provides an opportunity for global androgen replacement therapy market expansion. The trend towards personalized medicine offers opportunities to tailor androgen replacement therapies based on individual patient characteristics, optimizing treatment outcomes and potentially increasing the global androgen replacement therapy market.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/androgen-replacement-therapy-market/
Global Androgen Replacement Therapy Market – Geographical Insight
The global androgen replacement therapy market is segmented into regions such as North America, Latin America, Europe, Asia-Pacific, the Middle East & Africa. North America is the largest market for global androgen replacement therapy due to the high prevalence of hormonal disorder and well-established healthcare infrastructure contribute to a significant market share. Asia-Pacific is a growing global androgen replacement therapy market due to increasing healthcare expenditure and a rising senior population in countries like Japan and China fuel market growth. Europe’s regulatory framework supports the market, with a focus on patient safety and product efficacy. The aging population in countries like Germany and the UK contributes to a growing demand for androgen replacement therapies.
Global Androgen Replacement Therapy Market – Key Development
- On April 6, 2023, The University of Warwick created a company called Medherant to develop the world’s only testosterone patch for menopause.
- On June 7, 2022, Halozyme announced the commercial launch of TLANDO™ an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.